Cost-effectiveness analysis of nivolumab plus ipilimumab plus two cycles of platinum-doublet chemotherapy versus platinum-doublet chemotherapy alone for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States-Reference-Cited by-同舟云学术

Cost-effectiveness analysis of nivolumab plus ipilimumab plus two cycles of platinum-doublet chemotherapy versus platinum-doublet chemotherapy alone for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States

Published:2022-06-06 Issue:1 Volume:25 Page:660-668
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Polyzoi Maria¹,Sandhu Hera²,Maervoet Johan³,Yuan Yong⁴,Chaudhary Mohammad A.⁴,Varol Nebibe⁵,Lee Adam⁵,Dale Peter²,Jones Cheryl²,Lubinga Solomon J.⁴,Penrod John R.⁴

Affiliation:

1. Parexel International, Stockholm, Sweden

2. Parexel International, London, UK

3. Parexel International, Wavre, Belgium

4. Bristol Myers Squibb, Princeton, NJ, USA

5. Bristol Myers Squibb, Uxbridge, UK

Funder

Bristol Myers Squibb

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2022.2048573

Reference48 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. American Cancer Society. Key statistics for lung cancer [Internet]. [updated 12 January 2021; cited 14 September 2021]. Available from: https://www.cancer.org/cancer/lung-cancer/about/key-statistics.html.

3. National Cancer Institute. SEER Cancer Statistics Review, 1975–2015 [Internet]. [updated April 2018; cited 5 November 2021]. Available from: https://seer.cancer.gov/csr/1975_2015/.

4. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer

5. Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical benefit analysis of PD-1 inhibitors in patients with advanced, recurrent or metastatic cervical cancer: a meta-analysis and systematic review;Frontiers in Immunology;2024-01-24

2. Cost-effectiveness of first-line immunotherapy for advanced non-small cell lung cancer with different PD-L1 expression levels: A comprehensive overview;Critical Reviews in Oncology/Hematology;2024-01

3. First-line tremelimumab plus durvalumab and chemotherapy versus chemotherapy alone for metastatic non-small cell lung cancer: a cost-effectiveness analysis in the United States;Frontiers in Pharmacology;2023-07-20